ARGENX SE
ARGX evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $63.00B
- Lead Asset:
- Efgartigimod IV (Phase 4)
What it means
What to watch
Prepared research question
What matters most for ARGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ARGX
ARGENX SE (ARGX) is a global immunology company focused on developing antibody fragment therapies targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases, with a marketed product VYVGART and a pipeline spanning multiple indications.
Key risk: Pipeline execution risk
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
$63.00B
Cash Runway
—
Lead Asset
Efgartigimod IV (Phase 4)
Next Catalyst
Phase2_Start · Oct 15, 2026Financial data as of Dec 31, 2025.
Tracking 2 pipeline candidates · 53 clinical trials · 3 catalysts · 2 FDA decisions for ARGENX SE.
Similar companies
ARGENX SE (ARGX) is a global immunology company focused on developing antibody fragment therapies targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases, with a marketed product VYVGART and a pipeline spanning multiple indications.
- Reported $1.13 billion in third quarter global product net sales as of 2025-10-30 [news].
- Cash and equivalents of $3,491.3M as of 2025-12-31 [sec].
- VYVGART Hytrulo Phase 3 ALKIVIA trial in autoimmune myositis met its primary endpoint with a 15.4-point mean advantage over placebo on Total Improvement Score at Week 52 (p=0.0011) [news · 2026-08-22].
- VYVGART became the first biologic to show efficacy specifically in ocular myasthenia gravis, supporting a planned supplemental FDA filing [news · 2026-04-20].
- Pipeline includes Phase 4 studies for efgartigimod in membranous nephropathy, lupus nephritis, and immune thrombocytopenia, and Phase 3 starts for empasiprubart in chronic inflammatory demyelinating polyneuropathy [pipeline][catalyst].
What works
- VYVGART has demonstrated clinical efficacy across multiple autoimmune indications, including a statistically significant Phase 3 win in autoimmune myositis (p=0.0011) [news · 2026-08-22].
- The company has a strong cash position of $3,491.3M as of 2025-12-31, providing financial runway for pipeline expansion [sec].
- VYVGART is the first biologic to show efficacy in ocular myasthenia gravis, potentially expanding its label and market [news · 2026-04-20].
- Multiple registrational study readouts are expected in 2026, indicating a rich near-term catalyst calendar [news · 2025-10-30].
What to weigh
- The company faces execution and clinical risk in expanding its immunology pipeline beyond VYVGART, with several Phase 2 and Phase 3 trials ongoing [news · 2026-08-28].
- Positive Phase 3 data for VYVGART in autoimmune myositis may embed high expectations, and current valuation suggests investors are paying a premium [news · 2026-08-28].
- The pipeline includes multiple competitors for efgartigimod in various indications, such as Takeda and Immunovant Sciences, which could pressure market share [pipeline].
From the filings
Quoted directly from source documents.
VYVGART Hytrulo Phase 3 ALKIVIA trial met its primary endpoint in autoimmune myositis.
“VYVGART Hytrulo produced a 15.4-point mean advantage over placebo on the Total Improvement Score, or TIS, at Week 52 in the combined immune-mediated necrotizing myopathy and dermatomyositis population. The difference was statistically significant, with a p-value of 0.0011.”
News · August 22, 2026
VYVGART is the first biologic to show efficacy in ocular myasthenia gravis.
“VYVGART became the first biologic to show efficacy specifically in ocular myasthenia gravis, supporting a planned supplemental FDA filing...”
News · April 20, 2026
Third quarter 2025 global product net sales of $1.13 billion.
“$1.13 billion in third quarter global product net sales”
News · October 30, 2025
Catalyst timeline
- 2026-10-15 · Phase2_Start: ARGX-121 in Primary IgA Nephropathy — Phase 2, multicenter, randomized, placebo-controlled study to evaluate efficacy, safety, and tolerability of ARGX-121 SC in adult participants with primary IgA nephropathy.
- 2026-12-01 · Phase2_Start: Empasiprubart in Guillain-Barré Syndrome — Phase 2, randomized, double-blinded, placebo-controlled study to assess efficacy and safety of empasiprubart as add-on therapy to IVIg in adult participants with Guillain-Barré syndrome.
- 2027-04-01 · Phase2_Start: Efgartigimod PH20 SC in Autoimmune Encephalitis — Global, multicenter, randomized, double-blinded, placebo-controlled Phase 2 study to evaluate efficacy, safety, and tolerability of efgartigimod PH20 SC in adult and adolescent participants with autoimmune encephalitis.
Risks & what to watch (3)›
Key risks
- Pipeline execution risk — Expanding pipeline beyond VYVGART carries clinical and regulatory risk; multiple Phase 2/3 trials ongoing [news · 2026-08-28].
- Competitive pressure on efgartigimod — Efgartigimod faces 4-6 competitors in various indications, including Takeda and Immunovant Sciences [pipeline].
- Valuation premium risk — Stock has risen 209.7% over 5 years, embedding high expectations that may not be met if pipeline milestones falter [news · 2026-08-28].
What to watch
- Supplemental FDA filing for VYVGART in seronegative generalized myasthenia gravis by year-end 2025 [news · 2025-10-30].
- ADAPT-OCULUS results in first half 2026 for ocular myasthenia gravis [news · 2025-10-30].
- Five registrational study readouts expected in 2026 from the immunology pipeline [news · 2025-10-30].
- Phase 2 starts for ARGX-121 in IgA nephropathy (2026-10-15), empasiprubart in Guillain-Barré syndrome (2026-12-01), and efgartigimod PH20 SC in autoimmune encephalitis (2027-04-01) [catalyst].
Sources: Catalysts · News · Pipeline · Generated October 12, 2026 · How we verify sources →
Run ARGENX SE through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ARGENX SE facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
No tracked pipeline phase
2 candidates
3 upcoming, next in ~1d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
474
Total value held
$18.27B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 4,991,034 | $3.64B |
| janus henderson group plc | 2,541,732 | $1.85B |
| capital world investors | 2,256,216 | $1.65B |
| artisan partners limited partnership | 1,467,982 | $1.07B |
| wellington management group llp | 1,021,457 | $745.9M |
| avoro capital advisors llc | 1,000,000 | $730.3M |
| blackrock, inc. | 808,337 | $590.3M |
| rtw investments, lp | 709,446 | $518.1M |
| invesco ltd. | 594,697 | $434.3M |
| morgan stanley | 560,711 | $409.5M |
Showing top 10 of 474 institutional holders of ARGENX SE. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 3.3%
- Days to cover
- 6.8
- Shares short
- 2,077,333
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ARGX short interestFrequently asked questions
What is the AI investment thesis for ARGENX SE?
ARGENX SE (ARGX) is a global immunology company focused on developing antibody fragment therapies targeting the neonatal Fc receptor (FcRn) to treat autoimmune diseases, with a marketed product VYVGART and a pipeline spanning multiple indications.
What is ARGENX SE's lead drug candidate?
ARGENX SE's most advanced tracked candidate is Efgartigimod IV (Phase 4) for Membranous Nephropathy; Lupus Nephritis; Immune Thrombocytopenia (ITP).
What is ARGENX SE's next catalyst?
ARGENX SE's next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy" — expected October 15, 2026.
Who is the CEO of ARGENX SE?
Ms. Karen Massey is the chief executive officer of ARGENX SE (ARGX).
Where is ARGENX SE headquartered?
ARGENX SE (ARGX) is headquartered in Amsterdam, Netherlands.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.